Press Release

NEA Promotes Sara Nayeem, M.D. to Partner

October 27, 2015

Chevy Chase, MD – October 27, 2015 – Global venture capital firm New Enterprise Associates, Inc. (NEA) today announced the promotion of Sara Nayeem, M.D., to Partner. Dr. Nayeem joined NEA's healthcare team in 2009 and is focused on investments in biopharma.

“This promotion recognizes Sara’s acumen as an investor and her deep commitment to the entrepreneurs and founders with whom she partners,” said David Mott, General Partner and head of NEA’s healthcare investing practice. “We are pleased to acknowledge her many contributions to NEA’s biopharma practice and to our firm, and look forward to her continued success in this new role.”    

Since joining NEA, Dr. Nayeem has made significant contributions to NEA’s biopharma practice. She serves on the boards of Mersana, Cydan, Vtesse and Therachon, and as a board observer for Loxo Oncology (LOXO), Ziarco, and Clementia. She previously served as a board observer for Tesaro (TSRO), Epizyme (EPZM), Omthera (acquired by AstraZeneca), and Zyngenia. She has also been involved in NEA’s investments in Prosensa (acquired by BioMarin), 3-V Biosciences, Edimer, XTuit, Proteostasis, and Psyadon.

Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley.

Sara concurrently earned her medical degree and MBA from Yale University, where she was a Yale MBA Scholar. She received her bachelor’s degree in biology (magna cum laude) from Harvard University.

About NEA

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $17 billion in cumulative committed capital since inception, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions. www.nea.com.